Entrada Therapeutics (NASDAQ:TRDA) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Entrada Therapeutics (NASDAQ:TRDA) in a research note released on Wednesday morning, Marketbeat reports. The brokerage issued an overweight rating on the stock.

Other equities analysts also recently issued research reports about the stock. Guggenheim upgraded shares of Entrada Therapeutics to a “strong-buy” rating in a report on Wednesday, February 11th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Entrada Therapeutics in a report on Friday, March 27th. Oppenheimer initiated coverage on shares of Entrada Therapeutics in a research note on Wednesday, January 28th. They issued an “outperform” rating and a $21.00 price objective on the stock. Wall Street Zen cut shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Entrada Therapeutics in a research report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $18.50.

Entrada Therapeutics Price Performance

NASDAQ TRDA opened at $13.48 on Wednesday. The stock’s fifty day moving average price is $11.74 and its 200 day moving average price is $9.58. Entrada Therapeutics has a 1 year low of $4.93 and a 1 year high of $13.66. The company has a market cap of $516.01 million, a price-to-earnings ratio of -3.90 and a beta of -0.15.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.94) EPS for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.38. The company had revenue of $1.30 million during the quarter, compared to analysts’ expectations of $7.41 million. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%. Research analysts expect that Entrada Therapeutics will post 1.12 earnings per share for the current year.

Insider Activity at Entrada Therapeutics

In related news, CFO Kory James Wentworth sold 11,388 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $13.02, for a total value of $148,271.76. Following the completion of the transaction, the chief financial officer directly owned 121,510 shares in the company, valued at $1,582,060.20. The trade was a 8.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Nathan J. Dowden sold 11,894 shares of Entrada Therapeutics stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $13.05, for a total transaction of $155,216.70. Following the completion of the transaction, the chief operating officer directly owned 198,588 shares of the company’s stock, valued at $2,591,573.40. The trade was a 5.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 39,475 shares of company stock valued at $508,069. Insiders own 8.11% of the company’s stock.

Hedge Funds Weigh In On Entrada Therapeutics

A number of large investors have recently bought and sold shares of TRDA. Allspring Global Investments Holdings LLC grew its holdings in Entrada Therapeutics by 9.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock valued at $176,000 after purchasing an additional 1,560 shares during the period. Alliancebernstein L.P. raised its stake in shares of Entrada Therapeutics by 7.1% during the 3rd quarter. Alliancebernstein L.P. now owns 24,320 shares of the company’s stock worth $141,000 after buying an additional 1,620 shares during the period. Great Lakes Advisors LLC lifted its position in shares of Entrada Therapeutics by 5.5% during the 4th quarter. Great Lakes Advisors LLC now owns 43,268 shares of the company’s stock valued at $445,000 after buying an additional 2,239 shares in the last quarter. Intech Investment Management LLC lifted its position in shares of Entrada Therapeutics by 15.7% during the 2nd quarter. Intech Investment Management LLC now owns 17,702 shares of the company’s stock valued at $119,000 after buying an additional 2,397 shares in the last quarter. Finally, Quadrature Capital Ltd grew its stake in Entrada Therapeutics by 13.5% in the 4th quarter. Quadrature Capital Ltd now owns 20,318 shares of the company’s stock valued at $209,000 after acquiring an additional 2,424 shares during the period. Institutional investors and hedge funds own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.